Evidence Investigator
Adaptable, Efficient & Comprehensive
Why Choose the Evidence Investigator?
- World’s first platform to consolidate both immunoassay and molecular diagnostics.
- Multiplexing capabilities of Biochip Technology supports accurate test results with CVs typically <10%.
- The Evidence Investigator has a throughput of 2376 tests per hour with up to 44 analytes screened per biochip.
- Reduced sample volume of 7-25uL is required, leaving more sample remaining for confirmatory testing.
- The Evidence Investigator can store up to 20,000 sample results and up to 500,000 sample test results.
- Multiplex testing delivers a fast and cost effective solution compared to traditional methods.
The Evidence Investigator is the no.1 choice for research, clinical, forensic, molecular, and veterinary testing. Renowned for its versatility, robustness and effective reporting methods, this compact, semi-automated benchtop platform offers efficient and comprehensive testing without compromising on accuracy. It is the perfect fit for medium throughput laboratories seeking maximum use of benchspace.
The Evidence Investigator is able to consolidate both immunoassay and molecular testing offering the most comprehensive test menu on the market, achieved through protein and DNA based biochips improving laboratory efficiency and reducing costs.
The Evidence Investigator
Meet the Evidence Investigator
The Evidence Investigator improves laboratory efficiency and helps to reduce cost by consolidating immunoassay and molecular diagnostics.
Using chemiluminescent as a measurement principle, the Evidence Investigator consistently delivers accurate results.
All data is analysed on-board, removing issues related to human error and result manipulation.
Meet the Biochip Carrier
Each biochip can have up to 49 Discrete Test Regions (DTR) allowing up to 44 tests to be carried out simultaneously.
A maximum of 6 biochips can be added to the one Biochip carrier on the Evidence Investigator.
A smaller sample volume is required due to multiplexing capabilities.
Using protein and DNA based biochips provides the user the ability to consolidate tests.
Evidence Investigator Test Menu
| SARS-COV-2 ARRAY | |||
| Pathogens | |||
| SARS-CoV-2 (COVID-19) | Sarbecovirus (SARS, SARS Like, SARS-CoV-2) | ||
| EXTENDED CORONAVIRUS ARRAY | |||
| Pathogens | |||
| SARS-CoV-2 (COVID-19) | Enterovirus A/B/C | Influenza A | Influenza B |
| Coronavirus 229E/NL63 | Middle East Respiratory Syndrome Coronavirus (MERS-CoV) | Sarbecovirus (SARS, SARS like, SARS-CoV-2) | Adenovirus A/B/C/D/E |
| Coronavirus OC43/HKUI | Rhinovirus A/B | ||
| SARS-CoV-2 IgG (RBD & NP) ARRAY | |||
| Antigens | |||
| Nucleocapsid Protein (NP) | Spike Receptor Binding Domain (RBD) |
| AKI Array | |||
| Lipocalin (NGAL) | Clusterin | Cystatin C | KIM-1 |
| ADHESION MOLECULES ARRAY | |||
| E-selectin | P-selectin | L-selectin | ICAM-1 |
| VCAM-1 | |||
| ANAEMIA ARRAY | |||
| Ferritin | Folate | Vitamin B12 | |
| ALZHEIMERS RISK ARRAY | |||
| Pan ApoE | ApoE4 | ||
| CEREBRAL ARRAY II | |||
| sTNFRI | NGAL | NSE | D-dimer |
| CKD ARRAY I | |||
| EGF | FABP1 | D-Dimer | IL-8 |
| MIP-1 α | sTNFRI | sTNFRII | |
| CKD ARRAY II | |||
| CYTOKINE ARRAY I | |||
| IL-1α | IL-1β | IL-2 | IL-4 |
| IL-6 | IL-8 | IL-10 | IFNγ |
| EGF | MCP-1 | TNFα | VEGF |
| CYTOKINE ARRAY IV | |||
| MMP-9 | sIL-2Rα | sIL-6R | sTNFRI |
| sTNFRII | |||
| CYTOKINE ARRAY V | |||
| IL-3 | IL-7 | IL-12p70 | IL-13 |
| IL-23 |
| FERTILITY ARRAY | |||
| Follicle Stimulating Hormone (FSH) | Luteinising Hormone(LH) | Prolactin Hormone (PRL) | Progesterone (PROG) |
| Estradiol (EST) | |||
| GASTROPANEL ARRAY | |||
| Pepsinogen I (PGI) | Pepsinogen II (PGII) | Gastrin 17 (G17) | |
| HELICOBACTER PYLORI ASSAY | |||
| Helicobacter Pylori (HP) |
| METABOLIC SYNDROME I ARRAY | |||
| Ferritin | IL-6 | Insulin | Leptin |
| Plasminogen Activator Inhibitor-1 (PAI-1) | Resistin | Tumour Necrosis Factor α (TNFα) | |
| METABOLIC SYNDROME II ARRAY | |||
| Adiponectin | C-reactive Protein (CRP) | Cystatin C | |
| PTH ASSAY | |||
| Parathyroid Hormone (PTH) | |||
| SHGB ASSAY | |||
| Sex Hormone-Binding Globulin (SHBG) | |||
| STROKE ARRAY | |||
| Soluble Tumour Necrosis Factor | Receptor 1 (sTNFR1) | Glial fibrillary acidic protein (GFAP) | IL-6 |
| Fatty acid binding protein 3 (FABP3) | D-Dimer | Parkinson Disease Protein 7 (PARK7) | Nucleoside Diphosphate Kinase A (NDKA) |
| Glutathione S-transferase, Pi (GSTP1) |
| TESTOSTERONE ASSAY | |||
| Testosterone | |||
| THYROID TOTAL ARRAY | |||
| Total thyroxine (TT4) | Total tri-iodothyronine (TT3) | Thyroid stimulating hormone (TSH) | |
| THYROID FREE ARRAY | |||
| Free thyroxine (FT4) | Free tri-iodothyronine (FT3) | Thyroid stimulating hormone (TSH) | |
| THYROID AUTO ANTIBODY ARRAY | |||
| Anti-thyroglobulin (TgAb) | Anti-thyroid peroxidase Antibody (TPOAb) | ||
| THYROID TBG ASSAY | |||
| Thyroxine Binding Globulin (TBG) | |||
| TISSUE DAMAGE ARRAY | |||
| Liver Fatty Acid Binding Protein-1 - FABP1 | Heart-Type Fatty Acid-Binding Protein - FABP3 | Adipose Fatty Acid Binding Protein - FABP4 | Epidermal Fatty Acid Binding Protein - FABP5 |
| Ileal Fatty Acid Binding Protein - FABP6 | Brain Fatty Acid Binding Protein - FABP7 | Testis Fatty Acid Binding Protein - FABP9 | |
| TUMOR PSA ARRAY | |||
| Free Prostate Specific Antigen (fPSA) | Total Prostate Specific Antigen (tPSA) | Carcinoembryonic Antigen (CEA) | |
| VITAMIN D ASSAY | |||
| Vitamin D |
| CARDIAC RISK PREDICTION | |||
| Target | SNP | Target | SNP |
| MIA3* | rs17465637 | LPA* | rs3798220 |
| 9p21 | rs10757274 | LPA* | rs10455872 |
| DAB2IP | rs7025486 | MRAS* | rs9818870 |
| CXCL12 | rs1746048 | LPL* | rs328 |
| ACE | rs4341 | LPL | rs1801177 |
| NOS3 | rs1799983 | SORT1*+ | rs646776+ |
| APOA5 | rs662799 | PCSK9 | rs11591147 |
| SMAD3 | rs17228212 | APOE* | rs429358 |
| APOB* | rs1042031 | APOE* | rs7412 |
| CETP | rs708272 | ||
| CHRONIC LUNG DISEASE (CLD) ARRAY | |||
| Viral | |||
| Adenovirus | Metapneumovirus | Respiratory syncytial virus A | Respiratory syncytial virus B |
| Rhinovirus A/B/C | Influenza virus A | Influenza virus B | |
| Bacterial | |||
| Achromobacter xylosoxidans | Bordetella pertussis | Burkholderia cepacia complex (21spp) | Burkholderia cenocepacia |
| Chlamydia pneumoniae | Haemophilus influenza | Moraxella catarrhalis | Mycoplasma pneumoniae |
| Non-tuberculous mycobacterium (15 spp) | Mycobacterium avium complex (4 spp) | Pandoraea species (5 spp) | Prevotella species (16 spp) |
| Pseudomonas aeruginosa | Staphylococcus aureus | Stenotrophomonas maltophilia | Streptococcus pneumoniae (21 spp) |
| Streptococcus species (19 spp) | Veillonella species (3 spp) | ||
| Fungal | |||
| Aspergillus fumigatus | Candida albicans | Exophialia dermatitidis | Scedosporium species (7 spp) |
| Antibiotic Resistance Markers | |||
| mecA (incl MRSA) |
| FAMILIAL HYPERCHOLESTEROLEMIA | |||
| LDLR 38 mutations | APOB 1 mutation | PCSK9 1 mutation | |
| APOB | PCSK9 | ||
| Mutation | Protein | Mutation | Protein |
| c.10580G>A | p.(Arg3527Gln) | c.1120G>T | p.(Asp374Tyr) |
| LDR | |||
| Mutation | Protein | Mutation | Protein |
| c.2292delA | p.(Ile764Metfs*2) | c.1187-10G>A | p.(=) |
| c.1444G>A | p.(Asp482Asn) | c.1048C>T | p.(Arg350*) |
| c.551G>A | p.(Cys184Tyr) | c.118delA | p.(Ile40Serfs*166) |
| c.1845+11C>G | p.(=) | c.1168A>T | p.(Lys390*) |
| c.693C>A | p.(Cys231*) | c.232C>T | p.(Arg78Cys) |
| c.933delA | p.(Glu312Serfs*58) | c.1587-1G>A | p.(=) |
| c.301G>A | p.(Glu101Lys) | c.1706-10G>A | p.(=) |
| c.313+1G>A | p.(=) | c.1796T>C | p.(Leu599Ser) |
| c.1706-1G>A | p.(=) | c.1436T>C | p.(Leu479Pro) |
| c.1706-1G>A | p.(Cys677Arg) | c.1474G>A | p.(Asp492Asn) |
| c.2029T>C | p.(Pro685Leu) | c.501C>A | p.(Cys167*) |
| c.2054C>T | p.(Trp483Arg) | c.662A>G | p.(Asp221Giy) |
| c.1447T>C | p.(Gly478Arg) | c.682G>T | p.(Glu228*) |
| c.1447T>C | p.(Asp72Thrfs*134) | c.1150C>T | p.(Gln384*) |
| c.214delG | p.(Trp87Gly) | c.938G>A | p.(Cys313Tyr) |
| c.259T>G | p.(Arg633Cys) | c.136T>G | p.(Cys46Gly) |
| c.1897C>T | p.(Asp227Glu) | c.2042G>C | p.(Cys681Ser) |
| c.681C>G | p.(Asn688Glnfs*29) | c.1618G>A | p.(Ala540Thr) |
| c.1285G>A | p.(Val429Met) | c.680_681delAC | p.(Asp227Glyfs*12) |
| KRAS, BRAF, PIK3CA ARRAY | |||
| KRAS Gene Targets | |||
| G12A | G12R | G12D | G12C |
| G12S | G12V | G13D | G13C |
| G13R | Q61K | Q61L | Q61R |
| Q61H(1) | Q61H(2) | A146T | A146P |
| BRAF Gene Targets | |||
| V600EG12R | |||
| PIK3CA Gene Targets | |||
| E542K | E545K | H1047R | |
| RESPIRATORY MULTIPLEX ARRAY II | |||
| Viral | |||
| Influenza A | Influenza B | Adenovirus A/B/C/D/E | Bocavirus 1/2/3 |
| Coronavirus 229E/NL63 | Coronavirus OC43/HKUI | Enterovirus A/B/C | Metapneumovirus |
| Parainfluenza virus 1 | Parainfluenza virus 2 | Parainfluenza virus 3 | Parainfluenza virus 4 |
| Respiratory syncytial virus A/B | Rhinovirus A/B/C | ||
| Bacterial | |||
| Legionella pneumophila | Bordetella pertussis | Chlamydophila pneumoniae | Haemophilus influenzae |
| Moraxella catarrhalis | Mycoplasma pneumoniae | Streptococcus pneumoniae |
| SEXUALLY TRANSMITTED INFECTION (STI) ARRAY | |||
| Pathogens | |||
| Chlamydia trachomatis (CT) | Neisseria gonorrhoea (NG) | Trichomonas vanginalis (TV) | Mycoplasma genitalium (MG) |
| Treponema pallidum (Syphilis) (TP) | Herpes simplex virus 1 (HSV-1) | Herpes simplex virus 2 (HSV-2) | Haemophilus ducreyi (HD) |
| Mycoplasma hominis (MH) | Ureaplasma urealyticum (UU) | ||
| URINARY TRACT INFECTION (UTI) ARRAY | |||
| Bacterial | |||
| Acinetobacter baumannii | Citrobacter freundii | Citrobacter koseri | Klebsiella aerogenes |
| Enterobacter cloacae | Enterococcus faecalis | Enterococcus faecium | Escherichia coli |
| Klebsiella oxytoca | Klebsiella pneumoniae | Morganella morganii | Proteus spp. |
| Pseudomonas aeruginosa | Providencia rettgeri | Providencia stuartii | Serratia marcescens |
| Staphylococcus aureus | Staphylococcus epidermidis | Staphylococcus saprophyticus | Streptococcus agalactiae (GBS) |
| Fungal | |||
| Candida albicans | |||
| Antibiotic Resistance Markers | |||
| mecA (incl MRSA) | Trimethoprim Resistance 1 | Trimethoprim Resistance 2 | Trimethoprim Resistance 3 |
| S mecA (incl MRSA) | Trimethoprim Resistance 4 | Trimethoprim Resistance 5 | Van A (Vancomycin Resistance A) |
| Van B (Vancomycin Resistance B) |
| DoA ARRAY I+ | |||
| Amphetamine | Barbiturates | Benzodiazepines I (Oxazepam) | Benzodiazepines II (Lorazepam) |
| Buprenorphine | Benzoylecgonine (Cocaine Metabolite) | Cannabinoids (THC) | Creatinine |
| Methadone | Methamphetamine | MDMA | Opiate |
| Phencyclidine (PCP) | Tricyclic Antidepressants (TCA) | ||
| DoA ARRAY II | |||
| Buprenorphine | Creatinine | Fentanyl | Generic Opioids |
| Ketamine | LSD | MDMA | Methaqualone |
| Oxycodone I | Oxycodone II | Propoxyphene | |
| DoA ARRAY ULTRA/DUID | |||
| Amphetamine | Barbiturates | Benzodiazepines I (Oxazepam) | Benzodiazepines II (Lorazepam) |
| Benzoylecgonine (Cocaine Metabolite) | Buprenorphine | Cannabinoids (THC) | Dextromethorphan |
| Fentanyl | Generic Opioids | Meprobamate | Methadone |
| Methamphetamine | Opiate | Oxycodone I | Oxycodone II |
| Phencyclidine (PCP) | Tramadol | Tricyclic Antidepressants (TCA) | Zolpidem |
| DoA HAIR ARRAY | |||
| Amphetamine | Benzodiazepine | Cannabinoids (THC) | Benzoylecgonine (Cocaine Metabolite) |
| Hydrocodone | Ketamine | Methamphetamine | Opiate |
| Oxymorphone | Phencyclidine (PCP) |
| NPS I | |||
| Bath Salts I (Mephedrone / Methcathinone) | Bath Salts II (α-PVP / MDPV) | Benzylpiperazines | Mescaline |
| Phenylpiperazines I | Phenylpiperazines II | Salvinorin | Synthetic Cannabinoids (JWH-018) |
| Synthetic Cannabinoids (UR-144/XLR-11) | Synthetic Cannabinoids (ABCHMINACA) | Synthetic Cannabinoids (AB-PINACA) | |
| NPS II | |||
| Acetylfentanyl | AH-7921 | Buprenorphine | Carfentanil/Remifentanil |
| Clonazepam | Etizolam | Furanylfentanyl | Mitragynine |
| MT-45 | Naloxone | Ocfentanyl | Sufentanil |
| U-47700 | W-19 |
